Automatic conversion of an antibiotic from IV to PO

BACKGROUND

Administration of antibiotics through the intravenous (IV) route can be associated with adverse events related to the catheter or peripheral IV site, higher costs, longer hospitalizations, and a higher carbon footprint than administering antibiotics orally. This document outlines the conditions in which antibiotics should be automatically converted from their IV to their po formulation, also known as sequential therapy. Change of an antibiotic to a *different* agent (eg step down to a narrow spectrum agent) is not within the scope of this document.

WHEN TO automatically convert from IV to po (by clinical pharmacist or treating MD)



*If any of these diagnoses, ID to be consulted before conversion from IV to po

ANTIBIOTICS FOR AUTOMATIC CONVERSION FROM IV TO PO

IV Regimen	Equivalent PO Regimen
Azithromycin[1] 500 mg IV q24h	Azithromycin 500 mg PO q24h[1]
Ciprofloxacin[2] 400 mg IV q12h	Ciprofloxacin 500 mg PO q12h
Ciprofloxacin[2] 400 mg IV q8h (*Pseudomonas* dosing)	Ciprofloxacin 750 mg PO q12h (*Pseudomonas* dosing)
Clindamycin 600 mg IV q8h	Clindamycin 300-450 mg PO q6h
Fluconazole 400 mg IV q24h	Fluconazole 400 mg PO q24h
Levofloxacin[2] 500 mg IV q24h	Levofloxacin 500 mg PO q24h
Linezolid 600 mg IV q12h	Linezolid 600 mg PO q12h
Metronidazole 500 mg IV q8h	Metronidazole 500 mg PO q8h
Moxifloxacin[2] 400 mg IV q24h	Moxifloxacin 400 mg PO q24h
Trimethoprim-sulfamethoxazole 160/800 mg IV q12h (i.e. TMP 160mg/SMX 800mg)	Trimethoprim-sulfamethoxazole 160/800 mg PO q12h (i.e. TMP 160mg/SMX 800mg)

[1]Oral bioavailability of azithromycin ranges from 34% to 52% but remains a good option for PO conversion because of excellent tissue penetration and prolonged half-life.

[2] Enteral feedings or co-administration of **multivalent cations** (e.g., calcium, iron, magnesium, aluminum) can impact absorption of fluoroquinolones through chelation, therefore decrease oral bioavailability - consult pharmacy to advise on optimal timing of administration

REFERENCES

1. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016 May 15;62(10):e51-77.
2. Béïque L, Zvonar R. Addressing concerns about changing the route of antimicrobial administration from intravenous to oral in adult inpatients. Can J Hosp Pharm. 2015;68(4):318–26.
3. Bundgaard H, Ihlemann N, Gill SU, Bruun NE, Elming H, Madsen T, et al. Long-Term Outcomes of Partial Oral Treatment of Endocarditis. N Engl J Med. 2019 Apr 4;380(14):1373-1374.
4. Cyriac JM, James E. Switch over from intravenous to oral therapy: A concise overview. J Pharmacol Pharmacother. 2014 Apr;5(2):83-7.
5. Harvey EJ, McLeod M, De Brún C, Ashiru-Oredope D. Criteria to achieve safe antimicrobial intravenous-to-oral switch in hospitalised adult populations: a systematic rapid review. BMJ Open. 2023 Jul 7;13(7):e068299.
6. Harvey EJ, Hand K, Weston D, Ashiru-Oredope D. Development of National Antimicrobial Intravenous-to-Oral Switch Criteria and Decision Aid. J Clin Med. 2023 Mar 7;12(6):2086.
7. Landersdorfer CB, Gwee A, Nation RL. Clinical pharmacological considerations in an early intravenous to oral antibiotic switch: are barriers real or simply perceived? Clin Microbiol Infect. 2023 Sep;29(9):1120-1125.
8. Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al; OVIVA Trial Collaborators. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med. 2019 Jan 31;380(5):425-436.
9. Mertz D, Koller M, Haller P, Lampert ML, Plagge H, Hug B, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009 Jul;64(1):188-99.
10. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1998 Aug;92(8):1032-9.
11. Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006 Dec 9;333(7580):1193.
12. Park SM, Kim HS, Jeong YM, Lee JH, Lee E, Song KH, et al. Impact of Intervention by an Antimicrobial Stewardship Team on Conversion from Intravenous to Oral Fluoroquinolones. Infect Chemother. 2017 Mar;49(1):31-37.
13. Shrayteh ZM, Rahal MK, Malaeb DN. Practice of switch from intravenous to oral antibiotics. Springerplus. 2014 Dec 9;3:717.
14. Tingsgård S, Bastrup Israelsen S, Jørgensen HL, Østergaard C, Benfield T. Early Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative Bacteremia. *JAMA Netw Open.* 2024;7(1):e2352314.
15. Wald-Dickler N, Holtom PD, Phillips MC, Centor RM, Lee RA, Baden R, et al. Oral Is the New IV. Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review. Am J Med. 2022 Mar;135(3):369-379.e1.

Drafted by Rachel Verret (Pharmacy Resident)
Reviewed by F.Bourdeau (pharmacy), S.Landry (pharmacy), K.Archambault (pharmacy) and M. Semret (Infectious Diseases)

Revised by ASP committee on 19Jun2025; approved by MUHC P&T committee on 17Dec2025